IDEXX(US:IDXX)2025-11-03 13:30Q3 2025 Financial Performance - Revenue reached $1,105 million, with a reported growth of +13% and organic growth of +12%[1] - Operating profit was $355 million[1] - Diluted earnings per share (EPS) stood at $3.40, reflecting a reported growth of +21% and comparable growth of +15%[1] - CAG (Companion Animal Group) revenue was $1,013 million, showing a reported growth of +14% and organic growth of +12%[1] - Water revenue reached $54 million, with a reported growth of +8% and organic growth of +7%[1] - LPD (Livestock, Poultry and Dairy) revenue was $34 million, demonstrating a reported growth of +17% and organic growth of +14%[1] 2025 Outlook - Revenue is projected to be between $4,270 million and $4,300 million, with a reported growth of 9.6% - 10.3% and organic growth of 8.8% - 9.5%[6,7] - Operating margin is expected to be 31.6% - 31.8%, with a reported margin expansion of 260 bps - 280 bps and comparable margin expansion of 80 bps - 100 bps[6,7] - EPS is forecasted to be $12.81 - $13.01, representing a reported growth of 20% - 22% and comparable growth of 12% - 14%[6,7] U.S. Companion Animal Practice Growth - As of September 30, 2025, U S total visits include clinical and non-clinical visits, there were an estimated ~330 million U S total visits in 2024[8,10] - Q3 2025 year-over-year growth in clinical visit was 2.0%[9] - Q3 2025 year-over-year growth in practice revenue was 4.5%[9]